Unknown

Dataset Information

0

Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis.


ABSTRACT:

Purpose

We aimed to investigate the role of apolipoprotein A-I (ApoA-I) as a predictor of prognosis and treatment efficacy of bevacizumab in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without bevacizumab.

Methods

We conducted a retrospective study on consecutive patients who were diagnosed with mCRC at Sun Yat-sen University Cancer Center. According to their pretreatment ApoA-I level, patients were divided into low- and high-ApoA-I groups. Propensity score-matched method was performed to balance baseline characteristics between two groups. Based on whether they accepted bevacizumab as a first-line therapy, patients were further divided into the chemo + bevacizumab group and the chemo group. Overall survival (OS) and progression-free survival (PFS) were assessed with Kaplan-Meier method, log-rank test, and Cox regression.

Results

The optimal cutoff value for the ApoA-I level was determined to be 1.105 g/l. In the propensity-matched cohort of 508 patients, low ApoA-I was significantly associated with inferior OS (P<.001) and PFS (P<.001) than high ApoA-I. Multivariate analysis showed that ApoA-I level was an independent prognostic maker of OS (P<.001) and PFS (P=.001). PFS (P<.001) in either the high- or low-ApoA-I groups could be extended significantly after the administration of bevacizumab, and patients with a high ApoA-I level also had a better OS in the chemo + bevacizumab group than the chemo group (P=.049).

Conclusions

Patients with a low ApoA-I level have poor prognoses, and they did not display an OS benefit from bevacizumab.

SUBMITTER: Quan Q 

PROVIDER: S-EPMC5334545 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis.

Quan Qi Q   Huang Yuanyuan Y   Chen Qi Q   Qiu Huijuan H   Hu Qiaozhen Q   Rong Yuming Y   Li Tingwei T   Xia Liangping L   Zhang Bei B  

Translational oncology 20170302 2


<h4>Purpose</h4>We aimed to investigate the role of apolipoprotein A-I (ApoA-I) as a predictor of prognosis and treatment efficacy of bevacizumab in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without bevacizumab.<h4>Methods</h4>We conducted a retrospective study on consecutive patients who were diagnosed with mCRC at Sun Yat-sen University Cancer Center. According to their pretreatment ApoA-I level, patients were divided into low- and high-ApoA  ...[more]

Similar Datasets

| S-EPMC9330455 | biostudies-literature
| S-EPMC5078087 | biostudies-literature
| S-EPMC7281921 | biostudies-literature
| S-EPMC8018298 | biostudies-literature
| S-EPMC4526665 | biostudies-literature
| S-EPMC7509313 | biostudies-literature
| S-EPMC4891042 | biostudies-literature
| S-EPMC10835931 | biostudies-literature
| S-EPMC8743134 | biostudies-literature
| S-EPMC7557089 | biostudies-literature